4//SEC Filing
Flexion Therapeutics Inc 4
Accession 0001104659-16-126661
CIK 0001419600operating
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 9:40 PM ET
Size
13.1 KB
Accession
0001104659-16-126661
Insider Transaction Report
Form 4
LUBASH BARBARA N
Director10% Owner
Transactions
- Purchase
Common Stock
2016-06-08$14.00/sh+4,194$58,716→ 20,739 total(indirect: See Footnote) - Purchase
Common Stock
2016-06-08$14.00/sh+710,091$9,941,274→ 3,511,670 total(indirect: See Footnote)
Holdings
- 388,683(indirect: See Footnote)
Common Stock
Bolzon Bradley J PhD
Director10% Owner
Transactions
- Purchase
Common Stock
2016-06-08$14.00/sh+4,194$58,716→ 20,739 total(indirect: See Footnote) - Purchase
Common Stock
2016-06-08$14.00/sh+710,091$9,941,274→ 3,511,670 total(indirect: See Footnote)
Holdings
- 388,683(indirect: See Footnote)
Common Stock
Warden Charles M
Director10% Owner
Transactions
- Purchase
Common Stock
2016-06-08$14.00/sh+4,194$58,716→ 20,739 total(indirect: See Footnote) - Purchase
Common Stock
2016-06-08$14.00/sh+710,091$9,941,274→ 3,511,670 total(indirect: See Footnote)
Holdings
- 388,683(indirect: See Footnote)
Common Stock
Praeger Robin L.
10% Owner
Transactions
- Purchase
Common Stock
2016-06-08$14.00/sh+710,091$9,941,274→ 3,511,670 total(indirect: See Footnote) - Purchase
Common Stock
2016-06-08$14.00/sh+4,194$58,716→ 20,739 total(indirect: See Footnote)
Holdings
- 388,683(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]The shares are held by Versant Venture Capital III, L.P. ("VVC III"). Versant Ventures III, LLC, a Delaware limited liability company ("VV III") serves as the sole general partner of VVC III. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and dispositive power over the shares held by VVC III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.
- [F2]The shares are held by Versant Side Fund III, L.P. ("VSF III"). VV III serves as the sole general partner of VSF III. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and dispositive power over the shares held by VSF III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.
- [F3]The shares are held by Versant Development Fund III, LLC ("Development III"). Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and investment authority over the shares held by Development III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.
Documents
Issuer
Flexion Therapeutics Inc
CIK 0001419600
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001419600
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 9:40 PM ET
- Size
- 13.1 KB